Shares of AbbVie Inc (NYSE: ABBV) were volatile in the after-hours session after it issued an updated outlook for 2015.
AbbVie expects diluted earnings per share of $4.25 to $4.45 on an adjusted basis, and $3.99 to $4.19 under Generally Accepted Accounting Principles (GAAP), for the full-year 2015.
The midpoint of the 2015 guidance range reflects adjusted EPS growth of more than 30 percent from AbbVie's previously communicated 2014 adjusted EPS guidance.
Analysts had expected 2015 adjusted earnings of $4.30. The company intends to further refine its 2015 guidance as the HCV launch progresses.
"AbbVie has delivered strong performance in our first two years as an independent company and we expect to continue building on that momentum in 2015 with a return to top-tier growth," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "In addition to generating strong financial results, our priorities this year include strong commercial and operational execution as well as advancement of our promising pipeline."
AbbVie recently traded at $67.52, nearly unchanged.
See more from Benzinga
-
Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing War
-
Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.